HCPLive Network

ADHD

Otezla (apremilast) is an oral, selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
Adding an antipsychotic medication, such as risperidone, to stimulant therapy and parent training may improve parent ratings for behavioral problems in children with attention-deficit/hyperactivity disorder, according to research published in the September issue of the Journal of the American Academy of Child & Adolescent Psychiatry.
Attention-deficit/hyperactivity disorder stimulant treatment in children is not associated with significant changes in growth, according to a study published online Sept. 1 in Pediatrics.
Maternal smoking and nicotine replacement therapy during pregnancy are associated with increased risk of attention-deficit/hyperactivity disorder in children, according to research published online July 21 in Pediatrics.

Although there are a wide variety of treatment options available for patients with attention deficit hyperactivity disorder, methods for finding the proper course of treatment are still under development.
In 2 recent clinical trials, a treatment for young patients diagnosed with attention deficit hyperactivity disorder reportedly demonstrated benefit over another currently used ADHD medication.
ADHD Upcoming Events
ADHD Latest News
ADHD Clinical Trials
ADHD Resources